PT - JOURNAL ARTICLE AU - Das, Aatreyee M. AU - Chitnis, Nakul AU - Burri, Christian AU - Paris, Daniel H. AU - Patel, Swati AU - Spencer, Simon E.F. AU - Miaka, Erick M. AU - Castaño, M. Soledad TI - Modelling the impact of fexinidazole use on human African trypanosomiasis transmission in the Democratic Republic of Congo AID - 10.1101/2021.06.09.21258601 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.09.21258601 4099 - http://medrxiv.org/content/early/2021/06/12/2021.06.09.21258601.short 4100 - http://medrxiv.org/content/early/2021/06/12/2021.06.09.21258601.full AB - Gambiense human African trypanosomiasis is a deadly disease that has been declining in incidence since the start of the Century, primarily due to increased screening, diagnosis and treatment of infected people. The main treatment regimen currently in use requires a lumbar puncture as part of the diagnostic process to determine disease stage and hospital admission for drug administration. Fexinidazole is a new oral treatment for stage 1 and non-severe stage 2 human African trypanosomiasis. The World Health Organization has recently incorporated fexinidazole into its treatment guidelines for human African trypanosomiasis. The treatment does not require hospital admission or a lumbar puncture for all patients, which is likely to ease access for patients; however, it does require concomitant food intake, which is likely to reduce adherence. Here, we use a mathematical model calibrated to case and screening data from Mushie territory, in the Democratic Republic of the Congo, to explore the potential negative impact of poor compliance to an oral treatment, and potential gains to be made from increases in the rate at which patients seek treatment. We find that reductions in compliance in treatment of stage 1 cases are projected to result in the largest increase in further transmission of the disease, with failing to cure stage 2 cases also posing a smaller concern. Reductions in compliance may be offset by increases in the rate at which cases are passively detected. Efforts should therefore be made to ensure good adherence for stage 1 patients to treatment with fexinidazole and to improve access to passive care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Bill and Melinda Gates Foundation through the NTD Modelling Consortium via the University of Oxford (OPP1184344). The funding supported AMD, NC, MSC, SEFS and SP. The views, opinions, assumptions or any other information set out in this article are solely those of the authors and should not be attributed to the funders or any person connected with the funders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee approval not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying the results presented in the study are available upon request, to researchers who meet the required criteria, from the World Health Organization HAT Atlas (contact via Dr. Jose Ramon Franco Minguell - francoj{at}who.int).